Dr. Shah on Key Findings From the KarMMa Trial in Multiple Myeloma

Video

In Partnership With:

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and oncologist, and an associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses key findings from the phase 2 KarMMA trial (NCT03361748) in relapsed/refractory multiple myeloma.

The KarMMa study was a pivotal open-label, single-arm, multicenter trial that evaluated the efficacy of the BCMA-directed CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory multiple myeloma, Shah says. Patients who participated in the trial had received at least 3 prior lines of therapy and had exposure to a proteasome inhibitor, an immunomodulatory agent, and a CD38-directed monoclonal antibody. Moreover, patients had to have progressive disease at the time of enrollment to the trial, Shah says.

The key findings of the study demonstrated that the overall response rate was 73% across all patients treated with ide-cel and 81% in the patients who received the ide-cel dose of 450 x 106 CAR+ T cells, Shah continues. The median progression-free survival (PFS) was 8.6 months in the overall population and 12.2 months in those who received the 450 x 106 CAR+ T cell dose, Shah says.

Additionally, the therapy was reported to be safe, Shah says. Any-grade cytokine release syndrome was observed in 84% of patients and consisted mostly of grade 1 or 2 events, Shah concludes. 

Related Videos
Hans C. Lee, MD
Ariel Grajales-Cruz, MD
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Jeffrey Zonder, MD
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute, City of Hope, chief medical officer, International Myeloma Foundation
Ricardo D. Parrondo, MD
A panel of 4 experts on gastrointestinal cancers